Other Pharmaceuticals — Revenue
Eli Lilly Other Pharmaceuticals — Revenue increased by 2.6% to $19.80B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 55.5%, from $12.73B to $19.80B. Over 4 years (FY 2021 to FY 2025), Other Pharmaceuticals — Revenue shows an upward trend with a 23.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests sustained demand for legacy or secondary products, while a decrease may indicate portfolio rationalization or the natural decline of older, off-patent drugs.
Detailed definition
This metric represents the total net sales generated from pharmaceutical products that fall outside of the company's pri...
Peer comparison
Peers often report this as 'Other' or 'Legacy' revenue, and it is typically compared against the growth rates of core blockbuster therapeutic segments to assess portfolio balance.
lly_segment_other_pharmaceuticals_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.74B | $6.77B | $8.00B | $7.81B | $6.49B | $6.94B | $7.30B | $6.96B | $8.31B | $9.50B | $9.35B | $8.77B | $11.30B | $11.44B | $13.53B | $12.73B | $15.56B | $17.60B | $19.29B | $19.80B |
| QoQ Change | — | +0.5% | +18.1% | -2.4% | -16.9% | +7.0% | +5.2% | -4.7% | +19.4% | +14.3% | -1.5% | -6.3% | +28.9% | +1.2% | +18.3% | -5.9% | +22.2% | +13.1% | +9.6% | +2.6% |
| YoY Change | — | — | — | — | -3.7% | +2.5% | -8.7% | -10.9% | +28.1% | +36.8% | +28.1% | +26.0% | +36.0% | +20.4% | +44.7% | +45.2% | +37.6% | +53.9% | +42.6% | +55.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's other pharmaceuticals — revenue?
- Eli Lilly (LLY) reported other pharmaceuticals — revenue of $19.80B in Q1 2026.
- How has Eli Lilly's other pharmaceuticals — revenue changed year-over-year?
- Eli Lilly's other pharmaceuticals — revenue increased by 55.5% year-over-year, from $12.73B to $19.80B.
- What is the long-term trend for Eli Lilly's other pharmaceuticals — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's other pharmaceuticals — revenue has grown at a 23.2% compound annual growth rate (CAGR), from $28.32B to $65.18B.
- What does other pharmaceuticals — revenue mean?
- The total revenue generated from the company's secondary or non-core pharmaceutical product lines.